UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $4
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $2 to $4.
Login to comment